Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis.

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI:10.1080/09546634.2022.2131298

Špela Šuler Baglama, Irena Peteln, Gregor B E Jemec

{"title":"Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis.","authors":"Špela Šuler Baglama, Irena Peteln, Gregor B E Jemec","doi":"10.1080/09546634.2022.2131298","DOIUrl":null,"url":null,"abstract":"Background: Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning.Objective: This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK.Methods: This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase.Results: 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents - 21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p = .252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy.Conclusion: Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3136-3142"},"PeriodicalIF":2.9000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2131298","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Inflammation of actinic keratoses (AK) was originally described with systemic 5-fluorouracil, and led to the development of topical fluorouracil. Similar observations using different chemotherapeutics may point to other drugs with a potential for repositioning.

Objective: This systematic review aims to evaluate chemotherapeutic agents linked to inflammation-induced cure of AK.

Methods: This systematic review was registered in PROSPERO (CRD42022346168) and followed PRISMA guidelines. A comprehensive literature search for eligible original articles written in English and published in peer-reviewed journals until July 13, 2022 was conducted in MEDLINE and Embase.

Results: 28 articles met inclusion criteria accounting for 36 patients (mean age 68.4 ± 8.3 years) with inflamed AK, exposed to 21 different chemotherapeutic agents - 21/36 (58.3%) received monotherapy and 15/36 (41.7%) received multidrug combinations. Regression was complete in 13/28 (46.4%) and partial in 14/28 (50.0%) of inflamed AK. Cure rates of inflamed AK in multidrug combinations were not superior to monotherapies (p = .252), leading to the observation that the majority of the former (14/15; 93.3%) encompassed one of five chemotherapeutic agents linked to AK inflammation also as a monotherapy.

Conclusion: Overall, inflammation partially/completely cured AK in 96.4% of patients (27/28). Taxanes, pemetrexed, and doxorubicin might have the potential for the management of AK.

查看原文本刊更多论文

炎症性光化性角化病作为化疗药物重新定位的生物标志物:一项系统综述和荟萃分析。

背景:光化性角化病(AK)的炎症最初是用全身5-氟尿嘧啶来描述的，并导致了局部氟尿嘧啶的发展。使用不同化疗药物的类似观察结果可能指向其他具有重新定位潜力的药物。目的:本系统综述旨在评价化疗药物与炎症诱导的AK治愈相关。方法:本系统评价在PROSPERO注册(CRD42022346168)，遵循PRISMA指南。在MEDLINE和Embase中对2022年7月13日之前发表在同行评审期刊上的符合条件的英文原创文章进行了全面的文献检索。结果:28篇文章符合纳入标准，36例患者(平均年龄68.4±8.3岁)炎症性AK，接受21种不同的化疗药物，其中21/36(58.3%)接受单一治疗，15/36(41.7%)接受多药联合治疗。炎性AK在13/28(46.4%)完全回归，14/28(50.0%)部分回归。多药联合治疗炎症性AK的治愈率并不优于单药治疗(p = .252)，导致观察到前者的大多数(14/15;93.3%)包括与AK炎症相关的五种化疗药物中的一种，也作为单一疗法。结论:总体而言，炎症部分/完全治愈AK的患者占96.4%(27/28)。紫杉烷、培美曲塞和阿霉素可能具有治疗AK的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.